143 related articles for article (PubMed ID: 38756745)
1. The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine.
Olson AW; Haapala JL; Hooker SA; Solberg LI; Borgert-Spaniol CM; Romagnoli KM; Allen CI; Tusing LD; Wright EA; Haller IV; Rossom RC
Health Aff Sch; 2023 Oct; 1(4):qxad051. PubMed ID: 38756745
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians.
Hooker SA; Crain AL; LaFrance AB; Kane S; Fokuo JK; Bart G; Rossom RC
Addict Sci Clin Pract; 2023 Feb; 18(1):10. PubMed ID: 36774521
[TBL] [Abstract][Full Text] [Related]
3. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
[TBL] [Abstract][Full Text] [Related]
4. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
Franz B; Dhanani LY; Hall OT; Brook DL; Simon JE; Miller WC
Harm Reduct J; 2023 Dec; 20(1):180. PubMed ID: 38129903
[TBL] [Abstract][Full Text] [Related]
5. Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care.
Krupp J; Hung F; LaChapelle T; Yarrington ME; Link K; Choi Y; Chen H; Marais AD; Sachdeva N; Chakraborty H; McKellar MS
South Med J; 2023 Apr; 116(4):333-340. PubMed ID: 37011580
[TBL] [Abstract][Full Text] [Related]
6. Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care.
Janet Ho J; Jones KF; Sager Z; Neale K; Childers JW; Loggers E; Merlin JS
J Pain Symptom Manage; 2022 Aug; 64(2):119-127. PubMed ID: 35561938
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine Waiver Attitudes Among Primary Care Providers.
Lai B; Croghan I; Ebbert JO
J Prim Care Community Health; 2022; 13():21501319221112272. PubMed ID: 35822763
[TBL] [Abstract][Full Text] [Related]
8. The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency.
Boggiano V; Gilmore Wilson C; Fagan EB; Kirk J; Bossenbroek-Fedoriw K; Tak CR
J Am Board Fam Med; 2020; 33(6):998-1003. PubMed ID: 33219079
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder.
Rossom RC; Sperl-Hillen JM; O'Connor PJ; Crain AL; Nightingale L; Pylkas A; Huntley KV; Bart G
Addict Sci Clin Pract; 2021 Jun; 16(1):37. PubMed ID: 34130758
[TBL] [Abstract][Full Text] [Related]
10. Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey.
Foti K; Heyward J; Tajanlangit M; Meek K; Jones C; Kolodny A; Alexander GC
Drug Alcohol Depend; 2021 Aug; 225():108811. PubMed ID: 34175786
[TBL] [Abstract][Full Text] [Related]
11. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
Speight C; Caiola C; Tyndall DE; Scott ES
J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
[TBL] [Abstract][Full Text] [Related]
12. Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder.
Solmeyer AR; Berger AT; Barton SL; Nguyen B; Bart GB; Grahan B; Bell HJ; DeVine KM; Merrick W
JAMA Health Forum; 2022 Nov; 3(11):e224149. PubMed ID: 36399352
[TBL] [Abstract][Full Text] [Related]
13. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
15. Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder.
Holland WC; Nath B; Li F; Maciejewski K; Paek H; Dziura J; Rajeevan H; Lu CC; Katsovich L; D'Onofrio G; Melnick ER
Acad Emerg Med; 2020 Aug; 27(8):753-763. PubMed ID: 32352206
[TBL] [Abstract][Full Text] [Related]
16. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.
Auty SG; Stein MD; Walley AY; Drainoni ML
J Subst Abuse Treat; 2020 Aug; 115():108032. PubMed ID: 32600629
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Resident Physicians' Knowledge of and Attitudes Towards Prescribing Buprenorphine for Patients With Opioid Use Disorder.
Shuey B; Lee D; Ugalde I; Borgan S; Bresnan C; Qureshi M; Mhaskar R; Oxner A
J Addict Med; 2021 May-Jun 01; 15(3):219-225. PubMed ID: 33079729
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
